EPOCH 48: BIOTECH MARKET RESEARCH $GPCR $ALT $PFE
Structure Therapeutics, AltImmune, Pfizer
Mark your calendars for the anticipated regulatory decision on Structure Therapeutics which has an upcoming PDUFA date on the calendar. The company will share data on 12-week weight loss, HbA1c and safety data from Cohort 5 of its double-blind, placebo-controlled phase 2a study of GSBR-1290. Options pricing indicates a potential move of 30% - investors are poised for a significant market impact.
As a bonus we will comment on AltImmune sharing a Ph2 readout on Friday from pemvidutide, their GLP-1/glucagon dual receptor agonist. While the stock immediately jumped on this news (+13%) we see potential for additional upside and potentially even a buy out given the Pfizer failure. The options data is pricing in a 40% move in December!
Every Monday we are out with public biotech research, profiling biotech companies with near term catalysts. This will focus primarily on the major market moving biotech events such as data readouts from the major scientific conferences as well as potential regulatory approvals.
We will not offer specific trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely materially drive stock prices (sometimes +/-100% in either direction).
Be sure to SUBSCRIBE to not miss.
HOW TO PLAY BIOTECH APPROVAL/DATA READOUTS ANNOUNCEMENTS
While biotech equities will move on news of announcement, often if there is high conviction in a positive read, a large run up ahead of the news will occur and the actual event turns into a sell the news event. Sometimes, investors wait for the actual event to make a long/short decision. And obviously if the news is disappointing (more often than not) the stock will tank.
This is not financial advice so you will have to make your own call on how to best play these events.
ALERT: Structure Therapeutics - 12-week weight loss, HbA1c and safety data from Cohort 5 of its double-blind, placebo-controlled phase 2a study of GSBR-1290
DATE: December, 2023
IMPLIED VOLATILITY: +/- 30%
BACKGROUND:
Keep reading with a 7-day free trial
Subscribe to BowTiedBiotech to keep reading this post and get 7 days of free access to the full post archives.